Form 4: Anterix Inc. Chief Legal Officer Granted Stock Options
SEC Form 4 Filing
Anterix Inc.'s Chief Legal Officer, Gena L. Ashe, was granted stock options for 37,275 shares, vesting over three years starting January 16, 2025.
Summary
- Gena L. Ashe, Chief Legal Officer & Corp Sec of Anterix Inc., was granted stock options to purchase 37,275 shares of common stock.
- The options have an exercise price of $27.83 per share.
- The options vest in three equal annual installments, starting on January 16, 2025.
- The options expire on January 16, 2035.
- Vesting is contingent upon Ms. Ashe's continued employment with Anterix.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of any negative issues.
Positives
- The stock option grant aligns the interests of the Chief Legal Officer with the company's long-term performance.
- The vesting schedule encourages continued service and commitment from the executive.
Risks
- The value of the stock options is dependent on the future performance of Anterix's stock price.
- If Ms. Ashe leaves the company before the options fully vest, she may forfeit some or all of the options.
Future Outlook
The stock options will vest over the next three years, contingent on the executive's continued employment.
Industry Context
Stock option grants are a common form of executive compensation in publicly traded companies, designed to incentivize performance and align management's interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation across various industries.
- The vesting schedule of three years is also a common practice to ensure long-term commitment from executives.
- The specific number of options and exercise price would be determined by the company's compensation policy and the executive's role and performance.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes management to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/16/2025 | Date of the stock option grant and the start of the vesting period. |
| 01/16/2035 | Expiration date of the stock options. |
| 01/21/2025 | Date the form was signed. |
Keywords
stock options, executive compensation, insider trading, Anterix Inc., ATEX, Gena L. Ashe, Chief Legal Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.